EMVision's R&D Tax Incentive and ASA Milestone Achievement

EMVision Medical Devices Limited (ASX:EMV) has received a cash rebate of $2,586,350 from its R&D tax incentive claim for the financial year ending 30 June 2023. Additionally, the Company has achieved an important milestone under its Project Agreement with the Australian Stroke Alliance (ASA), triggering a $600,000 non-dilutive milestone payment.

Executive Commentary

The Company is pleased to have received the R&D tax incentive cash rebate and to have achieved a significant milestone with the Australian Stroke Alliance. These developments reflect our commitment to advancing our research and development activities and our dedication to contributing to the medical field. We remain focused on leveraging these funds to further our projects and drive innovation in medical device technology.

Summary of EMVision's Announcement

EMVision (ASX:EMV) has successfully received a cash rebate of $2,586,350 through the Australian Federal Government's R&D Tax Incentive Program for the financial year ending 30 June 2023. The Company has also triggered a $600,000 non-dilutive milestone payment by achieving an important milestone under its Project Agreement with the Australian Stroke Alliance. These achievements demonstrate EMVision's commitment to advancing its research and development activities. Looking ahead, the Company aims to utilize these funds to further its projects and drive innovation in medical device technology. It is important to note the inherent risks associated with investment in companies specializing in medical device development, and EMVision recommends seeking professional investment advice prior to making such investments.